|
|
Volumn 1, Issue 8, 2002, Pages 571-572
|
|
Value of novelty? Market indicators
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADRENERGIC RECEPTOR;
ANGIOTENSIN RECEPTOR;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BUSPIRONE;
CARVEDILOL;
CLOPIDOGREL;
DOPAMINE RECEPTOR;
FAMOTIDINE;
FEXOFENADINE;
FLUOXETINE;
G PROTEIN COUPLED RECEPTOR;
GOSERELIN;
HISTAMINE RECEPTOR;
HORMONE RECEPTOR;
IPRATROPIUM BROMIDE;
LORATADINE;
LOSARTAN POTASSIUM;
METOPROLOL;
MISOPROSTOL;
MONTELUKAST;
MUSCARINIC RECEPTOR;
NEW DRUG;
OLANZAPINE;
RANITIDINE;
RISPERIDONE;
ROPINIROLE;
SALMETEROL XINAFOATE;
SEROTONIN RECEPTOR;
SUMATRIPTAN SUCCINATE;
UNINDEXED DRUG;
CELL SURFACE RECEPTOR;
GUANINE NUCLEOTIDE BINDING PROTEIN;
COST;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG TARGETING;
HUMAN;
HYPERTENSION;
INVESTMENT;
MEDICAL DECISION MAKING;
MEDICAL TECHNOLOGY;
NOTE;
PRIORITY JOURNAL;
PRODUCTIVITY;
RISK ASSESSMENT;
SURVIVAL RATE;
TREATMENT FAILURE;
ARTICLE;
CHEMISTRY;
DRUG DELIVERY SYSTEM;
METHODOLOGY;
PHARMACEUTICS;
DRUG DELIVERY SYSTEMS;
GTP-BINDING PROTEINS;
RECEPTORS, CELL SURFACE;
TECHNOLOGY, PHARMACEUTICAL;
|
|
EID: 0036691412
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd884 Document Type: Note |
|
Times cited : (165)
|
|
References (2)
|
